SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Por Nuijten, M, Mickisch, G
Publicado em 2010

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Por Nuijten, M, Mickisch, G
Publicado em 2010

Practical issues in handling data input and uncertainty in a budget impact analysis

Por Nuijten, M. J. C., Mittendorf, T., Persson, U.
Publicado em 2010

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Por Mickisch, G H J, Escudier, B, Walzer, S, Nuijten, M
Publicado em 2010

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Por Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M
Publicado em 2010

Microeconomic Surplus in Health Care: Applied Economic Theory in Health Care in Four European Countries

Por Walzer, S., Nuijten, M., Wiesner, C., Kaier, K., Johansson, P-O., Oertel, S.
Publicado em 2013

Nutrition economics – characterising the economic and health impact of nutrition

Por Lenoir-Wijnkoop, I., Dapoigny, M., Dubois, D., van Ganse, E., Gutiérrez-Ibarluzea, I., Hutton, J., Jones, P., Mittendorf, T., Poley, M. J., Salminen, S., Nuijten, M. J. C.
Publicado em 2011

Workshop Report: concepts and methods in the economics of nutrition – gateways to better economic evaluation of nutrition interventions

Por Lenoir-Wijnkoop, I., Nuijten, M. J. C., Gutiérrez-Ibarluzea, I., Hutton, J., Poley, M. J., Segal, L., Bresson, J. L., van Ganse, E., Jones, P., Moreno, L., Salminen, S., Dubois, D.
Publicado em 2012